Positive data for intracerebral haemorrhagic stroke drug
Bioxodes has shared promising interim results from the BIRCH Phase IIa clinical trial of its lead asset, BIOX-101, to treat intracerebral haemorrhagic stroke (ICH). Interim analysis from the first 16 patients in the trial showed that primary safety and secondary efficacy endpoints were met. “While… Read More